On February 28, 2023 ImmuneOncia (CEO Kim Heung-tae), a new drug development company specializing in immuno-anticancer drugs, reported on the 28th that it signed a comprehensive business agreement (MOU) with April Bio (CEO Cha Sang-hoon) to establish a strategic cooperation system for joint development of new immuno-anticancer antibody drugs (Press release, ImmuneOncia Therapeutics, FEB 28, 2023, View Source;idx=19 [SID1234643372]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through this agreement, the two companies will use ImmuneOncia’s new antibody drug development technology, including ‘IMC-001’, an antibody treatment targeting PD-L1, and ‘IMC-002’, an antibody treatment targeting CD47, as well as April Bio’s proprietary platform SAFA (Serum). We plan to conduct joint research and promote mutual exchanges for the development of immunotherapy drugs using Albumin Fragment Associated (Albumin Fragment Associated) technology .

April Bio’s SAFA technology is an antibody fragment utilization platform that can increase the half-life of recombinant proteins and produce useful new antibody drugs.

Kim Heung-tae, CEO of ImmuneOncia, said, "Through this business agreement, we expect to further strengthen our ability to develop new immuno-anticancer antibody drugs based on the synergy between the two companies."

Sang-Hoon Cha, CEO of April Bio, said, "This agreement has great significance in that the excellence of the SAFA platform technology has been highly evaluated," adding, "Collaboration with ImmuneOncia, which has excellent antibody development capabilities, is expected to greatly contribute to the successful development of new drugs in the future. "I do it," he said.